Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Kanadische Plattform zur vergleichenden Wirksamkeit der Intensivpflege (CEPEC)

11. November 2026 aktualisiert von: Université de Sherbrooke

Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en Soins Critiques (CEPEC)

The Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en soins Critiques (CEPEC) is an international multi-centered randomized adaptive platform clinical trial. CEPEC will evaluate supportive care interventions that are used routinely in intensive care units throughout the world.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Many supportive therapies used daily in the ICU setting remain under-studied despite being resource-intensive. CEPEC aims to incorporate domains evaluating vasopressors and inotropes, nutrition, transfusions, sedation, correction of electrolyte deficits, sedation and analgesia, airway management, end-of-life care practices and other interventions.

Domains refer to categories of patient care for which interventions are being evaluated in a randomized controlled trial (RCT) within the platform.

VASOPRESSOR DOMAIN The investigators will investigate whether vasoactive medications should be used differently for different subgroups of patients who are in a state of cardiovascular shock (i.e. heterogeneity of treatment effects). Vasoactive medications are common in critically ill patients, and have considerable patient, hospital, and health system resource impact, but their use remains poorly supported by scientific evidence.

PLATELET DOMAIN Platelet transfusions are commonly prescribed to critically ill patients and have considerable patient, hospital, and health system resource impact, but remain poorly supported by scientific evidence. We propose to join a multicentre randomized clinical trial (T4P, ISRCTN79371664) addressing the optimal use of platelet transfusions for critically ill patients with thrombocytopenia in advance of invasive procedures. A multinational collaboration will ensure timely completion of this high-impact multicentre randomized clinical trial. The Canadian component of the T4P trial is embedded in the CEPEC platform as the Platelet Domain.

NUTRITION DOMAIN Most critically ill patients cannot eat normally and require a specialized method of feeding, called enteral nutrition. It is provided every hour around the clock. This differs from how we usually eat, with meals (boluses) divided over the day while we are awake. The goals of this study are to determine if a large study can be successfully done comparing nutrition given 3 times a day (boluses) compared to given in small amounts every hour (continuously).

INITIATIVES Initiatives are cross-cutting non-randomized studies nested within the platform that are relevant to all domains. Examples include a parallel observational study initiative, which aims to collect data about usual care and outcomes directly relevant to each domain. The goal is to describe the representativeness of domain results and to assess for protocol misalignment. Similarly, the living knowledge synthesis and health economics initiatives aim to generate meta-analyses and cost-effectiveness analyses alongside each trial conducted in the platform.

Studientyp

Interventionell

Einschreibung (Geschätzt)

5500

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • New Brunswick
      • Moncton, New Brunswick, Kanada, E1C 2Z3
        • Rekrutierung
        • Centre hospitalier universitaire Dr-Georges-L.-Dumont
        • Kontakt:
        • Hauptermittler:
          • Rémi Leblanc
    • Ontario
      • Brampton, Ontario, Kanada, L6R 3J7
        • Rekrutierung
        • William Osler Health System
        • Kontakt:
        • Hauptermittler:
          • Alexandra Binnie
      • Hamilton, Ontario, Kanada, L8L 2X2
        • Rekrutierung
        • Hamilton General Hospital
        • Kontakt:
        • Hauptermittler:
          • Kimia Honarmand
      • Hamilton, Ontario, Kanada, L8V 1C3
        • Rekrutierung
        • Hamilton Health Sciences - Juravinski Hospital
        • Kontakt:
        • Hauptermittler:
          • Bram Rochwerg
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Rekrutierung
        • The Ottawa Hospital
        • Kontakt:
        • Hauptermittler:
          • Alexandre Tran
      • Scarborough Village, Ontario, Kanada, M1P 2V5
        • Rekrutierung
        • Scarborough Health Network
        • Kontakt:
        • Hauptermittler:
          • Christopher Yarnell
      • St. Catharines, Ontario, Kanada, L2S 0A9
      • Toronto, Ontario, Kanada, M4N 3M5
        • Rekrutierung
        • Sunnybrook Health Sciences Centre
        • Kontakt:
        • Hauptermittler:
          • Neill Adhikari
    • Quebec
      • Longueuil, Quebec, Kanada, J4V 2H1
      • Montreal, Quebec, Kanada, H2X 0C1
        • Rekrutierung
        • Centre hospitalier de l'Université de Montréal (CHUM)
        • Kontakt:
        • Hauptermittler:
          • Francois-Martin Carrier
      • Montreal, Quebec, Kanada, H4J 1C5
        • Rekrutierung
        • CIUSSS NIM - Hôpital du Sacré-Coeur-de-Montréal
        • Kontakt:
        • Hauptermittler:
          • Yiorgos Alexandros Cavayas
      • Sherbrooke, Quebec, Kanada, J1H 5N4
      • Auckland, Neuseeland
        • Noch keine Rekrutierung
        • Auckland City Hospital
      • London, Vereinigtes Königreich
        • Noch keine Rekrutierung
        • Intensive Care National Audit and Research Centre (coordinating centre for sites in UK. Sites to be determined)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

VASOPRESSOR DOMAIN There is no minimum age limit in the Vasopressor Domain.

Inclusion criteria:

  1. Ongoing vasopressor infusion to treat hypotension, or would be used to treat clinician-defined hypotension as part of usual care;
  2. MAP <75 mmHg at any point;
  3. Patient expected to be in the ICU for >24 hours.

Exclusion criteria:

  1. Treating team does not have equipoise for at least two contiguous MAP target ranges in the CEPEC Vasopressor Domain;
  2. Acute traumatic brain injury (within 7 days or ongoing active treatment for elevated intracranial pressure);
  3. Acute subarachnoid hemorrhage (within 21 days);
  4. Acute spinal cord injury (within 7 days of injury or ongoing vasopressor therapy for suspected spinal cord ischemia);
  5. Lung, heart, liver, kidney transplant recipient (within 7 days);
  6. Patient expected to become an organ donor (Donor Neurologic Death - DND or Donation After Circulatory Death - DCD);
  7. More than 24 hours since meeting inclusion criteria in the ICU;
  8. Previously randomized into the CEPEC Vasopressor Domain or a confounding trial.

PLATELET DOMAIN

Inclusion criteria:

  1. Adult patients (age ≥18 years) admitted to the ICU;
  2. Latest platelet count in this hospital admission <50×109/L;
  3. Planned to undergo a specified low-moderate bleeding risk invasive procedure.

Exclusion criteria:

  1. Ongoing major hemorrhage requiring blood products and/or surgical/ radiological intervention;
  2. Intracranial hemorrhage within prior 72 hours;
  3. Contraindications to platelet transfusion (e.g. thrombotic microangiopathies, heparin-induced thrombocytopenia, recent history of immune thrombocytopaenia, congenital platelet function defects);
  4. Known advance decision of refusing blood/blood component transfusions;
  5. Acute promyelocytic leukemia (APML);
  6. Death perceived as imminent or admission for palliation;
  7. Previously randomized into the CEPEC Platelet Domain or the T4P Trial;
  8. Fulfilled all the inclusion criteria and none of the exclusion criteria ≥72 hours.

NUTRITION DOMAIN

Inclusion criteria:

  1. Patient of ≥18 years of age;
  2. Patient is invasively mechanically ventilated (including endotracheal tube or tracheostomy);
  3. Orogastric/nasogastric tube in place; or have an in dwelling percutaneous gastric tube (with confirmed placement);
  4. Treating team has started or has the intention of providing enteral nutrition.

Exclusion criteria:

  1. Patient who has had gastrointestinal (GI) surgery in the last 3 months and deemed not ready to receive possible bolus nutrition;
  2. Bowel obstruction or ischemia; active;
  3. Has a post-pyloric small bowel feeding tube;
  4. Active GI bleeding;
  5. Patient who is chronically receiving enteral nutrition.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Sonstiges: Vasopressor

Participants will receive vasopressor(s) and their mean arterial pressure will be titrated according to the group they are randomized to (group 1: 56-60 mmHg; group 2: 61-65 mmHg; group 3: 66-70 mmHg; group 4: 71-75 mmHg). Physicians will have the liberty of restricting the randomization to at least 2 contiguous ranges.

Vasopressor(s) will be titrated according to 56-60 range.

Vasopressor(s) will be titrated according to 61-65 range.

Vasopressor(s) will be titrated according to 66-70 range.

Vasopressor(s) will be titrated according to 71-75 range.

Sonstiges: Platelet

Thrombocytopenic intensive care unit (ICU) patients (platelet count <50×109/L) with a planned low-moderate bleeding-risk procedure will be randomized to one of five equally spaced platelet thresholds (less than 10 x 109/L, less than 20 x 109/L, less than 30 x 109/L, less than 40 x 109/L, less than 50 X 109/L) below which they will receive prophylactic platelet transfusions before any low-moderate bleeding-risk procedure occurring during the ICU episode up to ICU day 90. Once randomized, the clinical team will administer a platelet transfusion according to the assigned threshold and the most recent platelet count at the time of the planned procedure.

Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 10 x 109/L at the time of the planned procedure.

Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 20 x 109/L at the time of the planned procedure.

Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 30 x 109/L at the time of the planned procedure.

Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 40 x 109/L at the time of the planned procedure.

Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 50 x 109/L at the time of the planned procedure.

Sonstiges: Nutrition

The intervention is bolus feeding (given 3 times a day to meet nutritional targets) with formula type left to the discretion of the precribing team. With 2 hours between each "feed".

The control is continuous feeding (over 24-hour period) with formula type left to the discretion of the prescribing team, which is the current standard of care.

Given 3 times a day.

Given over 24-hour period

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Platelet Domain - All cause mortality
Zeitfenster: 90 days

90-day all-cause mortality

90 days
Nutrition Domain - Recruitment rate
Zeitfenster: 1 year

Recruitment rate of 2 patients per site per month.

1 year
Vasopressor Domain - 30-day ordinal outcome
Zeitfenster: At hospital discharge up to day 30

Incorporate mortality, persistent organ dysfunction (POD) in the ICU, hospitalization, discharge to a location providing more health services than at the patient's baseline residence, and discharge to baseline level residence.

At hospital discharge up to day 30

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Thrombozytendomäne - Mortalität bei der Entlassung aus dem Krankenhaus
Zeitfenster: Entlassung aus dem Krankenhaus
Entlassung aus dem Krankenhaus
Thrombozytendomäne - Mortalität nach 1 Jahr
Zeitfenster: 1 Jahr nach der Randomisierung
1 Jahr nach der Randomisierung
Thrombozytendomäne - Blutungen im Krankenhaus (Major und tödliche Blutungen)
Zeitfenster: Während des Krankenhausaufenthaltes
Während des Krankenhausaufenthaltes
Thrombozytendomäne - Tage lebendig und zu Hause am Tag 90 zu Hause
Zeitfenster: 90 Tage
90 Tage
Platelet Domain - Transfusion complications
Zeitfenster: During hospitalization

Transfusion-associated circulatory overload, transfusion-related acute lung injury, infections, anaphylaxis

During hospitalization
Platelet Domain - Health-related quality of life
Zeitfenster: 90 days

Evaluated using EQ-5D-5L questionnaire

90 days
Nutrition Domain - Diarrhea
Zeitfenster: 24 hours

Defined by the World Health Organization (WHO) definition (3 or greater liquids stools/24 hours)

24 hours
Nutition Domain - Percentage of target nutritional intake
Zeitfenster: Over the course of the ICU stay up to day 30

>80%

Over the course of the ICU stay up to day 30
Nutrition Domain - Vomiting
Zeitfenster: During ICU stay up to day 30

Vomiting 2 or more times in a 24-hour period

During ICU stay up to day 30
Vasopressor, Platelet and Nutrition Domains - Each component of the 30-day ordinal primary outcome
Zeitfenster: At hospital discharge up to day 30
  1. Mortality
  2. POD in the ICU
  3. Hospitalization
  4. Discharge to a location providing more health services than at the patient's baseline residence
  5. Discharge to baseline level residence.
At hospital discharge up to day 30
Vasopressor, Platelet and Nutrition Domains - Days free of POD to day 30
Zeitfenster: At hospital discharge up to day 30

POD is defined as a vasopressor infusion, invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen (delivered via nasal prongs or cannula by a specialized device, with a FiO2 ≥0.4 and at a flow rate ≥30L/min), or new renal replacement therapy.

At hospital discharge up to day 30
Vasopressor, Platelet and Nutrition Domains - Hospital days up to day 30
Zeitfenster: Up to day 30
Up to day 30
Vasopressor, Platelet and Nutrition Domains - ICU days to day 30
Zeitfenster: Up to day 30
Up to day 30
Platelet Domain - Number of days without POD in the ICU
Zeitfenster: Up to day 90
Up to day 90

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Francois Lamontagne, MD, MSc, Université de Sherbrooke
  • Hauptermittler: Neill Adhikari, MDCM, MSc, Sunnybrook Research Institute

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

23. März 2025

Primärer Abschluss (Geschätzt)

31. Dezember 2029

Studienabschluss (Geschätzt)

30. Juni 2030

Studienanmeldedaten

Zuerst eingereicht

10. September 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. September 2024

Zuerst gepostet (Tatsächlich)

20. September 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • MP-31-2025-5600

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .